Search
Paclitaxel Treatment Options in Idaho
A collection of 117 research studies where Paclitaxel is the interventional treatment. These studies are located in the Idaho, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
109 - 117 of 117
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as efaproxiral may make the tumor cells more sensitive to radiation therapy. It is not yet known if chemotherapy combined with radiation therapy is more effective with or without efaproxiral in treating non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of chem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2013
Locations: North Idaho Cancer Center, Coeur d'Alene, Idaho
Conditions: Lung Cancer
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of combining doxorubicin, cyclophosphamide, and paclitaxel with or without filgrastim in treating women who have inflammatory or locally advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho +2 locations
Conditions: Breast Cancer
S9912 Combination Chemo in Stage III Ovarian Cancer,
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, cisplatin, and liposomal doxorubicin in treating women who have undergone surgery for stage III ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/02/2013
Locations: St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2012
Locations: St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho
Conditions: Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Completed
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2012
Locations: St. Luke's/Mountain State Tumor Institute (MSTI), Boise, Idaho
Conditions: Non-small Cell Lung Cancer
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/06/2012
Locations: Mountain States Tumor Institute, Boise, Idaho
Conditions: Breast Cancer
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Completed
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/08/2012
Locations: North Idaho Cancer Center, Coeur d'Alene, Idaho
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
Terminated
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Mountain State Tumor Institute, Boise, Idaho
Conditions: Breast Neoplasm
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: Idaho Cardiology Associates, Boise, Idaho
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
109 - 117 of 117
